Crinetics Pharmaceuticals (CRNX) News Today → A new way to collect income from stocks (From DTI) (Ad) Free CRNX Stock Alerts $43.01 -1.00 (-2.27%) (As of 04:35 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineInsider Selling: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Sells 14,375 Shares of Stockinsidertrades.com - April 18 at 6:17 AMCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Sells $639,256.25 in Stockmarketbeat.com - April 17 at 6:38 PMCrinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 7.8%americanbankingnews.com - April 14 at 6:08 AMCrinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)finanznachrichten.de - April 12 at 8:19 AMCrinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)finance.yahoo.com - April 11 at 8:29 PMCrinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - April 11 at 4:05 PMCrinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Up 5.1%marketbeat.com - April 11 at 4:01 PMCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) CEO Sells $2,013,560.67 in Stockinsidertrades.com - April 9 at 4:20 AMVanguard Group Inc. Increases Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)marketbeat.com - April 5 at 4:07 AMCrinetics Pharmaceuticals (NASDAQ:CRNX) Sees Large Volume Increasemarketbeat.com - April 3 at 4:50 PMCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Director Stephanie Okey Sells 17,500 Sharesinsidertrades.com - April 3 at 4:58 AMCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of "Moderate Buy" from Analystsmarketbeat.com - April 3 at 2:20 AMCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Sees Significant Growth in Short Interestmarketbeat.com - April 2 at 7:18 PMCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Director Sells $811,650.00 in Stockmarketbeat.com - April 2 at 6:38 PMCrinetics Pharmaceuticals (NASDAQ:CRNX) Hits New 1-Year High at $48.00marketbeat.com - April 1 at 9:26 AMCrinetics Pharmaceuticals COO sells shares worth over $1.4 millioninvesting.com - March 28 at 6:13 PMInsiders Are Dumping These 5 Healthcare Stocksinsidermonkey.com - March 28 at 1:12 PMCrinetics Pharmaceuticals' (CRNX) "Market Outperform" Rating Reaffirmed at JMP Securitiesmarketbeat.com - March 28 at 11:29 AMInsider Sell: COO Jeff Knight Sells 32,359 Shares of Crinetics Pharmaceuticals Inc (CRNX)finance.yahoo.com - March 27 at 10:54 AMInsider Selling: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) COO Sells 32,359 Shares of Stockinsidertrades.com - March 27 at 4:57 AMCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) COO Jeff E. Knight Sells 32,359 Sharesmarketbeat.com - March 26 at 6:41 PMCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Dana Pizzuti Sells 15,089 Sharesinsidertrades.com - March 23 at 8:48 AMCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Sells $664,821.34 in Stockmarketbeat.com - March 22 at 8:10 PMDirector Matthew Fust Sells 60,000 Shares of Crinetics Pharmaceuticals Inc (CRNX)finance.yahoo.com - March 22 at 7:30 PMInsider Sell: Chief Medical and Development Officer Dana Pizzuti Sells 15,089 Shares of ...finance.yahoo.com - March 22 at 7:30 PMEquities Analysts Set Expectations for Crinetics Pharmaceuticals, Inc.'s FY2025 Earnings (NASDAQ:CRNX)marketbeat.com - March 22 at 8:38 AMCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) CFO Marc Wilson Sells 6,942 Sharesinsidertrades.com - March 21 at 9:46 AMBuy Rating Affirmed for Crinetics Pharmaceuticals on Paltusotine’s Clinical Success and Market Potentialmarkets.businessinsider.com - March 21 at 7:34 AMBuy Rating Affirmed for Crinetics Pharmaceuticals Amid Impressive Paltusotine Trial Resultsmarkets.businessinsider.com - March 21 at 7:34 AMCrinetics Pharmaceuticals Inc CFO Marc Wilson Sells 6,942 Sharesfinance.yahoo.com - March 21 at 7:34 AMCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) CFO Sells $297,881.22 in Stockmarketbeat.com - March 20 at 7:36 PMCrinetics Pharmaceuticals (NASDAQ:CRNX) Shares Gap Down to $45.18marketbeat.com - March 20 at 12:45 PMCrinetics Pharmaceuticals (NASDAQ:CRNX) Price Target Raised to $55.00marketbeat.com - March 20 at 12:32 PMCrinetics Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:CRNX)marketbeat.com - March 20 at 11:34 AMShort Interest in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Increases By 5.1%marketbeat.com - March 19 at 9:20 PMCrinetics Pharmaceuticals Up on Positive Results for Acromegaly Drug Trialmarketwatch.com - March 19 at 8:38 PMAnalysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and Biogen (BIIB)markets.businessinsider.com - March 19 at 3:38 PMEndocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here's Whybenzinga.com - March 19 at 3:38 PMCrinetics Stock Jets 16% Higher, Reversing A Three-Week Decline On Its Phase 3 Winfinance.yahoo.com - March 19 at 3:38 PMCrinetics Pharmaceuticals (NASDAQ:CRNX) Receives Buy Rating from HC Wainwrightmarketbeat.com - March 19 at 12:41 PMCrinetics Pharmaceuticals (NASDAQ:CRNX) Shares Gap Up to $37.93marketbeat.com - March 19 at 11:51 AMCrinetics Pharma Reports Positive Results From Phase 3 Studies Of Paltusotine For Acromegalymarkets.businessinsider.com - March 19 at 8:17 AMCrinetics Pharma's hormonal disorder drug meets main goal in late-stage studyreuters.com - March 19 at 8:17 AMCrinetics gains as late-stage trial for lead drug succeedsmsn.com - March 19 at 8:17 AMCrinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patientsfinance.yahoo.com - March 19 at 8:17 AMUPDATE 2-Crinetics' hormonal disorder drug succeeds in late-stage studyfinance.yahoo.com - March 19 at 8:17 AMBiotech Stock Crinetics Jets Higher On Second Phase 3 Trial Winfinance.yahoo.com - March 19 at 8:17 AMCrinetics' Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patientsglobenewswire.com - March 19 at 6:00 AMCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Purchased by Wellington Management Group LLPmarketbeat.com - March 18 at 4:53 AMBuy Rating Affirmed for Crinetics Pharmaceuticals as Paltusotine Shows Promising Phase 2 Results and Market Potentialmarkets.businessinsider.com - March 13 at 9:53 AM Get Crinetics Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Biden to Launch “FedNOW” [Move Your Money Now] (Ad)Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar... Get your free information kit NOW, before it's too late. CRNX Media Mentions By Week CRNX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRNX News Sentiment▼0.310.49▲Average Medical News Sentiment CRNX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRNX Articles This Week▼84▲CRNX Articles Average Week Get Crinetics Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Arrowhead Pharmaceuticals News Today Xenon Pharmaceuticals News Today IDEAYA Biosciences News Today Bausch Health Companies News Today HUTCHMED News Today Amicus Therapeutics News Today Prestige Consumer Healthcare News Today Axsome Therapeutics News Today ACADIA Pharmaceuticals News Today MoonLake Immunotherapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRNX) was last updated on 4/18/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Report[Urgent!] Generational Wealth GameplanCrypto 101 MediaThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe “Perfect Storm” for GoldGold Safe ExchangeBiden’s $374B Giveaway Into This SectorDTIHe Is Giving Away BitcoinCrypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.